COVID-19 Adenoviral Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT), COVID-19-Related Thrombosis, and the Thrombotic Thrombocytopenic Syndromes

Adenoviral-based vaccines such as ChadoX1 CoV-19 (AstraZeneca) and Ad26.COV2.S (J&J) were developed to prevent infection and reduce hospitalization or death in Coronavirus Disease 2019 (COVID-19) patients. Although these vaccines passed safety and efficacy trials with excellent neutralizing capa...

Descripción completa

Detalles Bibliográficos
Autores principales: Allas, Gewil Daniella Olipas, Arizala, Joekeem Del Rosario, Manalo, Rafael Vincent Mercado
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9778187/
https://www.ncbi.nlm.nih.gov/pubmed/36547234
http://dx.doi.org/10.3390/hematolrep14040050

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9778187/
https://www.ncbi.nlm.nih.gov/pubmed/36547234
http://dx.doi.org/10.3390/hematolrep14040050

Ejemplares similares